Amundi Asset Management US’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q1 | $509M | Buy |
14,037,210
+4,114,833
| +41% | +$146M | 0.39% | 57 |
|
|
2020
Q4 | $365M | Buy |
9,922,377
+214,349
| +2% | +$7.86M | 0.31% | 74 |
|
|
2020
Q3 | $338M | Buy |
9,708,028
+1,425,837
| +17% | +$50M | 0.35% | 62 |
|
|
2020
Q2 | $257M | Buy |
8,282,191
+1,023,316
| +14% | +$34.8M | 0.3% | 69 |
|
|
2020
Q1 | $225M | Sell |
7,258,875
-2,873,151
| -28% | -$97.9M | 0.39% | 58 |
|
|
2019
Q4 | $377M | Buy |
10,132,026
+621,029
| +7% | +$22.1M | 0.44% | 46 |
|
|
2019
Q3 | $324M | Sell |
9,510,997
-3,562,844
| -27% | -$130M | 0.48% | 38 |
|
|
2019
Q2 | $1.53B | Buy |
13,073,841
+81,858
| +0.6% | +$3.25M | 1.25% | 13 |
|
|
2019
Q1 | $523M | Sell |
12,991,983
-6,349,773
| -33% | -$254M | 0.74% | 25 |
|
|
2018
Q4 | $15.8M | Buy |
19,341,756
+1,162,815
| +6% | +$48.3M | 14.54% | 2 |
|
|
2018
Q3 | $760M | Buy |
18,178,941
+1,522,304
| +9% | +$58.6M | 1% | 12 |
|
|
2018
Q2 | $573M | Buy |
16,656,637
+504,801
| +3% | +$17.3M | 0.83% | 14 |
|
|
2018
Q1 | $544M | Sell |
16,151,836
-3,973,229
| -20% | -$137M | 0.87% | 15 |
|
|
2017
Q4 | $692M | Buy |
20,125,065
+9,025,779
| +81% | +$308M | 1.07% | 10 |
|
|
2017
Q3 | $376M | Buy |
11,099,286
+1,105,012
| +11% | +$35.5M | 1.2% | 18 |
|
|
2017
Q2 | $319M | Buy |
9,994,274
+672,318
| +7% | +$21.2M | 1.04% | 22 |
|
|
2017
Q1 | $303M | Sell |
9,321,956
-666,681
| -7% | -$21M | 1.02% | 22 |
|
|
2016
Q4 | $308M | Sell |
9,988,637
-4,616,991
| -32% | -$141M | 1.08% | 25 |
|
|
2016
Q3 | $469M | Sell |
14,605,628
-1,719,026
| -11% | -$57.5M | 1.69% | 7 |
|
|
2016
Q2 | $545M | Buy |
16,324,654
+5,078,489
| +45% | +$162M | 1.98% | 6 |
|
|
2016
Q1 | $316M | Buy |
11,246,165
+2,624,437
| +30% | +$75M | 1.17% | 19 |
|
|
2015
Q4 | $264M | Buy |
8,621,728
+2,701,188
| +46% | +$85M | 0.99% | 26 |
|
|
2015
Q3 | $176M | Buy |
5,920,540
+999,298
| +20% | +$32M | 0.72% | 34 |
|
|
2015
Q2 | $157M | Sell |
4,921,242
-1,056,945
| -18% | -$34.4M | 0.57% | 49 |
|
|
2015
Q1 | $197M | Buy |
5,978,187
+271,466
| +5% | +$8.63M | 0.71% | 32 |
|
|
2014
Q4 | $169M | Buy |
5,706,721
+2,004,309
| +54% | +$57.5M | 0.61% | 46 |
|
|
2014
Q3 | $104M | Sell |
3,702,412
-3,679,494
| -50% | -$103M | 0.39% | 80 |
|
|
2014
Q2 | $208M | Sell |
7,381,906
-1,738,767
| -19% | -$49.6M | 0.8% | 23 |
|
|
2014
Q1 | $278M | Sell |
9,120,673
-394,475
| -4% | -$11.8M | 1.06% | 12 |
|
|
2013
Q4 | $277M | Sell |
9,515,148
-470,283
| -5% | -$13.7M | 1.06% | 13 |
|
|
2013
Q3 | $272M | Sell |
9,985,431
-530,703
| -5% | -$14.4M | 1.1% | 10 |
|
|
2013
Q2 | $279M | Buy |
+10,516,134
| New | +$291M | 1.16% | 11 |
|
Other funds holding PFE
Amundi Asset Management US's PFE Position: Q1 2021 in Review
Amundi Asset Management US increased its Pfizer (PFE) stake by 41% in Q1 2021, buying an estimated $146M and bringing the position to 14,037,210 shares worth $509M. The position accounts for 0.39% of the portfolio, ranked #57.
Amundi Asset Management US first reported a position in PFE in Q2 2013 and has held it in 32 quarters since. The position peaked at $1.53B in Q2 2019. 2,676 funds tracked by Wall St. Rank hold PFE as of Q1 2021.
- Amundi Asset Management US held 14,037,210 shares of Pfizer worth $509M as of Q1 2021.
- Amundi Asset Management US bought 4,114,833 Pfizer shares in Q1 2021, an estimated $146M.
- Pfizer made up 0.39% of Amundi Asset Management US's portfolio in Q1 2021, its #57 holding.
- Amundi Asset Management US first reported a position in Pfizer in Q2 2013 and has held it in 32 quarters since.
- Amundi Asset Management US's Pfizer position peaked at $1.53B in Q2 2019.
- 2,676 funds tracked by Wall St. Rank held Pfizer as of Q1 2021.
Based on Amundi Asset Management US's 13F filing for Q1 2021, filed 17 May 2021.